The endothelin (ET) family consists of three 21-amino acid peptides designated ET-1, 2] . The biological actions of the ETs are primarily mediated by two distinct, G-protein-coupled receptor subtypes designated ET A and ET B [2] . Endothelin A receptors have a higher affinity for ET-1 and ET-2 than ET-3 and the ET B receptor binds all three isoforms with equal affinity. Translation of preproET mRNA generates preproET, which is converted to big ET and finally cleaved by ET converting enzyme (ECE) to facilitate production of biologically active peptide. Endothelin-1 released by vascular endothelial cells exerts an autocrine influence by promoting vasodilatation, subsequent to activation of ET B receptors located on endothelial cells. It also exerts a paracrine effect on adjacent vascular smooth muscle cells (VSMC) in evoking vasoconstrictor and mitogenic actions by activation of both ET A and ET B receptors. The primary target of ET-1 is the vasculature where it evokes transient vasodilatation mediated by endothelial ET B receptors, followed by slow-onset and sustained contraction mediated by ET A and ET B receptors located on VSMC. The functional response to ET-1 varies throughout different tissues and vascular beds due to differences in distribution and expression of these two receptor subtypes. Endothelin-1 Diabetologia (1999) 
also induces contraction and increases inotropy in cardiac muscle, regulates salt and water homeostasis through actions in the kidney, stimulates the reninangiotensin and sympathetic nervous systems, contracts pulmonary airway and vascular smooth muscle and induces hypertrophy of vascular, mesangial and cardiac muscle [2] . Importantly, ET-1 is thought to act as a modulator of basal vascular tone.
By maintaining a critical balance between relaxing and contracting factors, the endothelium regulates both vascular tone and growth. Accordingly, the vasoconstrictor and mitogenic actions of ET-1 are opposed by vasodilator and antigrowth factors such as endothelial-derived relaxing factor (EDRF) and prostacyclin secreted by endothelial cells [3] . Key metabolic variables that are changed in diabetes mellitus such as plasma insulin, glucose and lipids are well known to directly regulate the release of ET-1 from endothelial cells as well as modulate receptor expression and responses to the peptide. Furthermore, prolonged and excessive exposure of both endothelial cells and VSMC to the metabolic dysregulation of diabetes mellitus could promote atherosclerotic and other morphological changes that indirectly affect the release and action of ET-1 at various target sites. Accordingly, alterations in ET-1 release and action have been consistently shown in both human diabetes mellitus and animal models of the disease. Morbidity associated with the diabetic state primarily results from pathological changes at the vascular level that logically fit with many of the known actions of ET-1. Thus, considerable interest has been generated towards defining the role of this peptide in the complications of the disease.
Endothelin-1 concentrations in normal and diabetic plasma
Endothelin-1 comprises the lion's share of circulating ETs, with the other isoforms ranging from undetectable to extremely low in concentration [4] . Moreover, endothelial cells produce almost exclusively ET-1. Thus, for the purposes of this review,`endothelins' are referred to as simply ET-1. Plasma concentrations of ET-1 range between 1 and 5 pmol rarely exceeding 25 pmol, even in pathological states [4] . Whereas this concentration range is inadequate to elicit many of the pharmacological actions of the peptide, the majority of endogenous ET-1 is released from endothelial cells abluminally towards the VSMC [5] and increases (decreases) in ET-1 plasma concentrations are thought to reflect overproduction (underproduction) and spillover (or lack of) of ET-1 from endothelial cells [6, 7] . Alterations in plasma ET-1 could, however, also reflect changes in renal, receptor or enzyme-mediated clearance of the peptide [2] . Consequently, plasma determinations of ET-1 are limited in that they cannot be regarded as a reliable estimate of synthesized, secreted, or active peptide with regard to effects on VSMC. Moreover, a recent study has questioned the reliability of plasma ET-1 concentrations as determined by RIA [8] . Nonetheless, some vascular beds are highly sensitive to pathophysiological increases in plasma ET-1 and its concentrations are increased in various cardiovascular disease states. Accordingly, several studies have examined the status of ET-1 in the plasma of both human diabetic patients and animal models of the disease.
The status of ET-1 plasma concentrations in Type I (insulin-dependent) diabetes mellitus is controversial. The streptozotocin (STZ) diabetic rat, a widely used model of insulin deficiency characteristic of Type I diabetes, has been shown to have increased plasma ET-1 after 8 weeks [7, 9±11] and attenuated concentrations before 5 weeks [11±14] of exposure to diabetes. Accordingly, the duration of diabetes appears to determine the direction of changes in plasma ET-1 in this animal model [11] . Caution is, however, warranted when interpreting plasma ET-1 concentrations in this model too soon after STZ treatment because actions of STZ itself cannot be ruled out. In patients with Type I diabetes, both increased [15±17] and decreased [18, 19] plasma ET-1 has been reported and in patients with Type II (non-insulin-dependent) diabetes mellitus plasma ET-1 has been reported to be both increased [20, 21] and unchanged [22, 23] . In addition to duration-dependent effects, interstudy variability in the metabolic state, level of control, presence of established macrovascular complications [16] and methodology for measuring ET-1 [8] are likely to contribute to such discrepancies. Importantly, we have shown that altered plasma ET-1 in diabetes can be restored to normal by restoration of metabolic control [14] .
In summary, although it is clear that plasma ET-1 is altered in diabetes, the nature and direction of these changes are not clear. Interstudy variability in study population and assay characteristics probably contribute to discrepancies. Future studies should be directed at determining the relevance and role of altered plasma ET-1 to the complications of the disease. Until the importance of changes in plasma ET-1 concentrations is more adequately defined, local and tissue ET-1 concentrations would provide a more relevant measure of pathological changes in ET.
In vitro vascular reactivity studies
Most ex vivo studies examining vascular responsiveness to vasoactive stimuli (including ET-1) in models of diabetes use the aorta as the prototype vessel. Endothelin-1 causes a potent, sustained contraction of this conduit vessel mediated primarily by ET A recep-tors present on VSMC. Attenuated vasoconstrictor responses to ET-1 (but not other agonists) are present in aorta from STZ rats as early as 2 weeks after induction of diabetes [9, 10, 24] . Such selectively attenuated responses have been attributed to ET receptor down regulation resulting from either protein kinase C activation or increased ET-1 production [25±27]. On the contrary, we and others have shown increased vasoconstrictor responses to ET-1 and other agonists in vascular tissue from STZ rats as early as 2 weeks after induction of diabetes [11, 14, 28, 29] . Such nonspecific increases in vasoconstriction might be attributed to modification of contraction resulting from either altered Ca 2+ channel expression and action [28] or protein kinase C activation [29] . Whatever the cause, this abnormality can be corrected by restoration of metabolic control [14] . Moreover, we have also shown that the trend towards exaggerated responses to ET-1 reverses and actually becomes slightly attenuated after long-term exposure to diabetes [11] . This occurs in conjunction with the development of endothelial dysfunction and increased plasma lipid concentrations. These data suggest that attenuated responses to ET-1 result from pathological changes occurring only after long-term exposure to diabetes. Thus, similar to ET-1 plasma concentrations, aortic reactivity to ET-1 is at least partly dependent on the pre-existing duration of diabetes.
We have also shown exaggerated ET-1 evokes vasoconstriction in aorta from hyperinsulinaemic/insulin resistant obese Zucker rats [30] . Exaggerated responses in this model, however, are non-specific, because similar results were seen with other agonists [31, 32] . This abnormality has been attributed to alterations in Ca 2+ channel activity in VSMC [31] and is restored by metabolic control [32] .
Although it is clear that altered vascular reactivity to ET-1 exists in models of diabetes, there are several limitations to existing studies. Firstly, there is minimal evidence examining vascular responses to ET-1 in diabetes in vascular beds other than aorta. As physiological responses to ET-1 vary amongst different vascular beds, there might be relevant tissue specific changes in reactivity to ET-1 in diabetes. Secondly, there is a high degree of interstudy variability in the methodology used to measure vasoconstriction. Although isometric tension methodology is the most popular method for measuring reactivity, variability in bathing medium, method of expressing reactivity and differing baseline tension applied by different laboratories make interstudy comparisons difficult. Finally, the physiological relevance of changes in aortic reactivity is questionable. The aorta is a conduit vessel thought to contribute little to peripheral resistance. Perfused arterial bed preparations have been developed which are thought to more adequately represent changes in vascular resistance [33] . Consequently, we have recently shown that although aorta from the obese Zucker rat has exaggerated vasoconstrictor responses to ET-1, mesenteric perfusion responses to the peptide remain unchanged [34] . We [35] and others [10] have, however, also shown that the perfused mesenteric arterial bed of STZ rats has selectively attenuated vasoconstrictor responses to ET-1.
In summary, limited in vitro vascular reactivity studies suggest that alterations in responsiveness to ET-1 exist in both conduit and resistance arteries in models of diabetes. There appears to be some degree of selectivity to these changes indicating that diabetes might affect specifically ET receptors or ET-1 signalling pathways. Some of the differences in responsiveness to ET-1 in diabetes might be related to changes in the relative proportions of ET A and ET B receptors. Unfortunately, few studies have examined changes in receptors or receptor subtypes for ET-1 in vascular tissues from diabetic animals. Indeed, the vascular effects of endogenous ET-1 could change in patients with diabetes if there are changes in number or function of ET A and ET B receptors in certain vascular beds. Furthermore, responses to ET-1 need to be more closely examined in other vascular beds and in smaller vessels where changes in ET-1 reactivity might be more relevant to diabetic pathology.
In vivo haemodynamic studies
The in vivo response to ET-1 varies in different vascular beds depending on expression and density of vasodilator ET B and vasoconstrictor ET A and ET B receptors. The integrated haemodynamic response to ET-1 consists of a transient drop in blood pressure followed by a slow and sustained increase in blood pressure [1] . The systemic depressor response to ET-1 results from vasodilation in the hindquarter and carotid vascular beds, although the renal and mesenteric vascular beds are constricted [36] . During the pressor phase, vasoconstriction predominates in all four vascular beds resulting in an increase in total peripheral resistance. Although cutaneous, splanchic, coronary, pulmonary and renal vascular beds are all potently contracted by systemically administered given ET-1, the latter three are most sensitive to the vasoconstrictor effects of ET-1 [2] . Moreover, studies with ET antagonists indicate that endogenously generated ET-1 acts as a basal regulator of blood pressure in healthy humans [37] .
Few studies have assessed haemodynamic responses to ET-1 in vivo in diabetic states. One study showed that renal and mesenteric vasoconstrictor responses to ET-1 were exaggerated in STZ rats whereas initial hindquarter vasodilator responses to ET-1 remained unchanged [38] . If similar effects occur in human diabetes, as the renal and mesenteric vasculatures are primary contributors to the pressor response to ET-1, increases in ET-1 reactivity in these beds might contribute to increased total peripheral resistance. Furthermore, the renal vasculature is known to be highly sensitive to physiological increases in plasma ET-1 [39] . Other recent studies show impaired pressor responses to ET-1 in vivo in diabetes [25, 40, 41] . Attenuated ET-1 evoked increases in blood pressure [25] and reductions in cutaneous blood flow [40] were observed as early as 2 weeks after induction of diabetes in STZ rats. The only study in human diabetes examining in vivo reactivity to ET-1 showed a lack of sensitivity to the vasoconstrictor effects of locally infused ET-1 in forearms of patients with Type II diabetes [41] . Increases in perfusion to various vascular beds (including skin and forearm) are well known to be one of the earliest haemodynamic changes associated with human diabetes [42] . Thus, it is plausible that resistance to the basal vasoconstrictor actions of ET-1 resulting in enhanced vasodilatation and excess tissue perfusion contributes to these early changes.
In summary, there are too few studies to draw definite conclusions on haemodynamic responses to ET-1 in diabetic states. Based on existing evidence, the haemodynamic actions of ET-1 in diabetes appear dependent on the pre-existing duration of diabetes, the status of endothelial function and vascular bed under consideration. Further studies are warranted examining haemodynamic responses to ET-1 in human diabetes. As ET-1 is thought to contribute to basal vascular tone, alterations in ET-1 reactivity might explain some of the haemodynamic alterations of the disease.
Role of ET-1 in the vascular complications of diabetes mellitus.
Hypertension. Hypertension occurs in diabetic patients at a greater incidence than in the general population and the combination of the two considerably accelerates the atherosclerotic process [43] . Endothelin-1 is well known to promote sustained increases in blood pressure [44] and a recent landmark study has shown that bosentan, a non-selective ET A /ET B antagonist, lowers blood pressure in patients with essential hypertension [45] . Thus, ET-1 is a plausible candidate mediator in the development of diabetic hypertension. One study showed that plasma ET-1 acts as a marker of hypertension in patients with type I diabetes [17] . However, in Type I diabetes, increased blood pressure usually develops, as a result of nephropathy [46] . In contrast, hypertension precedes renal damage in Type II diabetes, but its cause is not known. Although plasma ET-1 was shown to be increased in Type II diabetes, those with both hypertension and macrovascular disease, but not with hypertension alone, had higher plasma ET-1 than those with uncomplicated Type II diabetes [47, 48]. Thus, based on limited current evidence, it appears unlikely that ET-1 contributes to hypertension in either Type I or Type II diabetes.
Atherosclerosis. Atherosclerotic vascular disease occurs in diabetic patients at a rate much higher than in the general population and macrovascular complications resulting from atherosclerosis are responsible for the greatest number of deaths associated with the disease [46] . Altered endothelial function occurring in diabetic states ultimately leads to smooth muscle proliferation, an integral feature of atherosclerosis [43] . There is considerable evidence supporting a role for ET-1 in the atherosclerotic process. Endothelin-1 production and plasma concentrations are increased in patients with atherosclerosis [6] and atherosclerotic human arteries have up-regulated ET-1 peptide expression [49] . The non-selective ET A /ET B receptor antagonist, bosentan, prevented neo-intima formation in a rabbit carotid artery model of atherosclerosis [50] , and selective ET A blockade reduced atheroma formation independent of plasma cholesterol and blood pressure [51] . Later studies confirmed that increased plasma ET-1 is a marker of atherosclerotic macrovascular disease in patients with Type II diabetes [47, 48, 52] . Furthermore, those with the highest ET-1 concentrations had both atherosclerosis and Type II diabetes [52] . Few other studies have examined the link between diabetes, atherosclerosis and ET-1. Nonetheless, the potent anti-proliferative effects of ET antagonists indicate that blockade of the ET system might have profound beneficial effects on atherosclerotic vascular disease in diabetic patients. Such effects might also be beneficial in reducing vascular remodelling, cardiac hypertrophy and renal glomerulosclerosis resulting from diabetes alone or in combination with hypertension. Neurovascular abnormalities. An early reduction in blood flow to peripheral nerves leading to endoneurial hypoxia contributes to nerve conduction deficits in diabetes [53] . Studies in STZ rats have established a possible role for ET-1 in the aetiology of attenuated endoneurial blood flow in diabetes. Sciatic axons in these rats are selectively susceptible to ischaemia induced by ET-1 due to more intense and prolonged vasoconstriction to the peptide [54] . Moreover, sciatic nerve motor conduction deficits in diabetic rats were corrected by an ET A antagonist, in association with increases in sciatic nutritive endoneurial blood flow [55] . Non-selective ET A /ET B blockade failed, however, to evoke similar actions [56] , indicating that the addition of ET B blockade might blunt the beneficial effects of ET A antagonism. Moreover, the addition of an angiotensin AT 1 receptor antagonist to diabetic rats already treated with an ET A antagonist conferred synergistic beneficial effects on nerve conduction [57] . Thus, there is considerable evidence that an in-creased vasoconstrictive capacity to ET-1 is present in the neurovasculature of diabetic animals. Moreover, efficacy of ET antagonists shown in such neurovascular abnormalities provides substantial evidence of a contributory role for the peptide in this complication.
Diabetic retinopathy. Abnormal retinal haemodynamics contribute to the development of diabetic retinopathy [58] . Endothelial cells and pericytes, which constitute the retinal microvasculature, act as the main regulators of retinal blood flow. Ocular tissue is a rich source of ET-1 peptide expression, and ET-1 has been shown to maintain ocular blood flow in vivo [59] . Accordingly, alterations in ET-1 production and action have been hypothesized to contribute to diabetic retinopathy and other ocular vascular diseases. Several in vitro studies have shown that hyperglycaemia can alter both production and responses to ET-1 in pericytes, the contractile cells of the retinal microcirculation. Exposure to increased concentration of glucose attenuated cellular signalling and functional contraction evoked by ET-1 in rat retinal pericytes [60, 61] . Later studies showed that increases in retinal circulation time after intravitreal injection of ET-1 and ET-3 were attenuated [62] in STZ rats and that altered retinal blood flow in these rats could be restored to normal by phosphoramidon, an ECE inhibitor [63] . PreproET mRNA was also increased twofold in the retina of diabetic rats compared with normal controls. These results implicate increases in endogenous ET-1 production and resistance to the vasoconstrictor actions of the peptide in retinal blood flow alterations in diabetes. There are few studies assessing the role of ET-1 in diabetic retinopathy in humans. One recent study showed ET-1 concentrations in the vitreous fluid of diabetic patients with proliferative retinopathy are actually decreased compared with non-diabetic control subjects [64] . Moreover, increased plasma ET-1 has been observed in Type II diabetic patients with retinopathy [65, 66] but without other end-organ damage related to diabetes [65] .
Nephropathy. The kidney is an important site of action for ET-1 [67] . Glomerular EC, mesangial cells, and epithelial cells secrete ET-1. Endothelin-1 constricts renal vessels, contracts mesangial cells, inhibits salt and water reabsorption, enhances glomerular proliferation and stimulates extracellular matrix accumulation. Although basal tone is only modestly maintained by ET-1, pathophysiological concentrations of ET-1 cause profound renal vasoconstriction with little effect on systemic blood pressure [39] .
Alterations in urinary [68, 69] , total renal [70, 71] , glomerular [72] and ureteral [73] ET-1 peptide, mRNA and receptor levels are present in animal models of diabetes. Studies with ET antagonists have also shown a role for this peptide in renal dysfunction in diabetes. Treatment for 24 weeks with the ET A receptor antagonist, FR139317, attenuated the fall in creatinine clearance and reduced urinary protein excretion and mRNA expression for extracellular matrix components and growth factors in glomeruli of STZ rats [74] . Another ET A antagonist, LU135252, decreased raised urinary ET-1 in STZ rats but only had modest effects on albumin excretion [75] . The non-selective ET A /ET B receptor antagonist, PD142893, restored renal blood flow to normal and reduced urinary protein and albumin excretion in proteinuric STZ rats to a similar extent as the angiotensin converting enzyme inhibitor, enalapril [76] . Once again, there are few studies examining renal ET-1 in humans with diabetes. Raised 24-h urinary ET-1 was present in Type II diabetic patients with albuminuria [77] and increases in circulating ET-1 preceded the microalbuminuric phase of renal damage related to diabetes [78] .
In summary, it is clear that alterations in urinary and renal ET-1 content are associated with diabetic nephropathy and this is another complication where ET antagonists have shown protective effects.
Hypoxia and ischaemia Endothelin-1 is a powerful constrictor of the cerebral and coronary vasculature capable of inducing hypoxia and ischaemia. Hypoxia itself promotes ET-1 synthesis in vivo in humans [79] , increases ET receptors in cardiac membranes [80] , and augments the contractile actions of ET-1 [81] . Consequently, ET-1 has been hypothesized to contribute to ischaemic damage in conditions such as myocardial infarction and stroke. Plasma concentrations of ET-1 are increased in acute myocardial infarction and are predictive of 1-year mortality in humans [82] and ET antagonists have shown beneficial effects in animal models of both ischaemic heart disease and stroke [83] . The hyperglycaemia of diabetes is known to induce a ªpseudohypoxicº state that mimics the effects of true hypoxia on vascular and neural function despite normal tissue partial pressure of oxygen [84] . Accordingly, diabetic patients are known to have increased susceptibility to hypoxic and ischaemic injury in myocardial and cerebral vessels [85, 86] . The link between ET-1, diabetes and ischaemic stroke or heart disease has, however, not yet been investigated. As hypoxia modulates the release and action of ET-1, it is plausible that the diabetic state potentiates these effects contributing to the greater susceptibility to ischaemic damage in diabetic patients.
Metabolic variables influencing ET-1 production and action in diabetes
From the above evidence, it is clear that the diabetic state is associated with changes in the release and action of ET-1 in nearly all of the target sites affected by the disease. Much of the evidence presented does not, however, prove a causal role for ET-1 in these complications, and existing human studies are limited to correlations of complications and metabolic control with plasma ET-1 concentrations. Recent evidence that ET antagonists beneficially affect some of these complications in animal models of diabetes provides the most compelling evidence to date that ET-1 might be pathogenic in diabetic vascular disease. A key question that remains is what are the factors responsible for the observed changes in ET-1 release and action in diabetes? Due to the plethora of metabolic and cardiovascular abnormalities present in Type I and Type II diabetes and differential effects of the various treatment options on these variables, isolating the causes of changes in ET-1 release and action assumes importance.
Hyperglycaemia. The precise role of high glucose in regulating the release and action of ET-1 is controversial. Hyperglycaemia, the primary metabolic disturbance of diabetes, has been shown to increase [87] , decrease [88] , and have no effect on [89, 90] the release of ET-1 from endothelial cells in culture. Species differences as well as the concentration and duration of incubation of glucose used by these studies probably account for these discrepancies. Studies examining the effect of high glucose on receptors and responses to ET-1 have also yielded somewhat equivocal results. Incubation of cultured aortic smooth muscle cells with high glucose decreased the maximum binding capacity (but not affinity) for ET-1 [13, 91] . In contrast, pericytes incubated with high glucose showed a statistically non-significant increase in receptors for ET-1 [60] . In both retinal pericytes [60, 61] and aortic smooth muscle cells [91] , contractile responses to ET-1 are blunted after high glucose incubation, apparently independent of effects on receptor expression. A summary of the effects of high glucose concentration on ET-1 release and action is shown in Figure 1 .
Insulin. Type II diabetes is often considered a hyperinsulinaemic state and patients with Type I diabetes on insulin therapy exhibit fluctuations between insulinaemia and glycaemia. Since the seminal discovery that insulin increases gene expression for ET-1 in cultured endothelial cells [92] , intense research has focused on explaining the relevance of this effect in pathological states characterized by elevated or fluctuating insulin concentrations. Physiological insulin concentrations are known to increase the release of ET-1 from both human endothelial cells [93] and VSMC [94] in culture and induction of hyperinsulinaemia increases plasma concentrations of ET-1 in humans [93, 95] and animals [13, 14] .
Studies have also shown an effect of insulin on changes in tissue reactivity to ET-1, both at the receptor and post receptor level. It was first shown in 1993 that preincubation with high concentrations of insulin increased ET receptor expression in aortic smooth muscle cells in vitro and long-term in vivo insulin delivery to normal and STZ rats increased ET receptors in various tissues [13] . We have recently confirmed these results showing that long-term insulin incubation selectively increases ET A receptor expression and cytosolic free calcium ([Ca 2+ ] i ) responses in rat aortic smooth muscle cells [30] . Further- Fig. 1 . Effects of high glucose on factors related to ET-1 production and action. Glucose regulates ET-1 peptide and receptor expression as well as responses to the peptide in vitro. The direction of these changes is, however, controversial. High glucose also increases endothelial derived relaxing factor production, through activation of nitric oxide synthase. It also inhibits endothelium derived relaxing factor (EDRF) through endothelial damage and other actions such as advanced glycation end product (AGE) and superoxide radical formation. Such actions could also regulate ET-1 production and action. more, ET A receptors are increased in vascular tissue from hyperinsulinaemic obese Zucker [30] and fructose hypertensive [96] rats, indicating possible physiological relevance to these findings. In contrast, short-term incubation of VSMC with insulin appears to have a suppressive effect on vascular responses evoked by ET-1 (as well as other agonists). Porcine coronary artery [Ca 2+ ] i [97] and contractile [98] responses to ET-1 were attenuated in the presence of physiological concentrations of insulin through an endothelium-independent mechanism. In endothelium-intact rat aortic rings in the presence of insulin, arterial contraction induced by potassium chloride was, however, exaggerated in a manner dependent on ET-1 [99] . Therefore it appears that the effect of insulin on smooth muscle responsiveness to ET-1 in vitro depends on both the term of exposure to insulin and on the presence or absence of intact endothelium for the release of ET-1.
In conclusion, insulin appears to be a modulator of ET-1 peptide, ET receptors and ET-1 mediated responses ± in both in vitro and in vivo settings (Fig. 2) . Hyperinsulinaemia itself has been hypothesized to contribute to accelerated vascular disease [46] . Thus, it is plausible that changes in ET-1 activity evoked by insulin could be pathophysiologically relevant. Studies examining the effects of long-term treatment with ET antagonists on vascular pathology in hyperinsulinaemic states would be useful in clarifying the significance of this interaction.
Lipids. Raised plasma lipoproteins are present in both Type I and Type II diabetic patients, particularly in those with poor metabolic control [46, 100] . Considerable evidence indicates a profound ability of plasma lipoproteins to affect both the release and action of ET-1. Oxidized LDL evokes a concentration and time dependent increase in preproET mRNA expression in porcine and human endothelial cells [101, 102] whereas only high concentrations of native VLDL and LDL have a similar effect [102] . Moreover, raised plasma lipids increase endothelial cell [103] , coronary [104] and plasma [95, 104] ET-1 concentrations in vivo. Furthermore, the effect of hyperlipidaemia on plasma ET-1 is synergistic with hyperinsulinaemia in humans [95] and plasma ET-1 is increased in patients with raised plasma lipoproteins even before the development of atherosclerosis [105] .
Similar to observations with insulin and glucose, raised lipids are capable of altering tissue responsiveness to ET-1. Hypercholesterolaemic rabbits show exaggerated vascular reactivity to vasoactive peptides, including ET-1, before the development of endothelial dysfunction [106] and pigs fed a high cholesterol diet for 10 weeks have accentuated coronary vasoconstrictor responses to ET-1 [107] . Thus, similar to both insulinaemia and hyperglycaemia, hyperlipidaemia in itself has the capability to regulate plasma concentrations of ET-1 as well as receptors and tissue reactivity to the peptide (Fig. 3) .
Endothelial dysfunction, EDRF action, and duration of disease. The nature of endothelial dysfunction in diabetes is controversial. Increased EDRF production is thought to occur in early diabetes due to nitric oxide synthase activation mediated by hyperglycaemia [108, 109] . It is, however, also well established that the metabolic dysregulation of diabetes is associated with inhibition of EDRF release and action through a multitude of direct and indirect actions (Fig. 4; [46,109] ). Considerable evidence implicates ] i responses evoked by ET-1. Insulin also increases EDRF formation by nitric oxide synthase activation differences in the duration of exposure to diabetes in determining the nature and direction of these changes. Although hyperglycaemia could activate EDRF production in the short term, as the duration of diabetes progresses, atherosclerotic changes [46] and other events such as advanced glycation end product [110] and superoxide radical formation [111] clearly promote pathological changes in endothelial function leading to suppressed EDRF action. Accordingly, a recent study showed that vasodilatation mediated by EDRF is accentuated in short term STZ rats but becomes paradoxically impaired with increasing duration of diabetes [112] . Moreover, we have recently observed attenuated EDRF-mediated vasodilatation in 14-week, but not 2 week, STZ rats [11] .
Alterations in EDRF in diabetes could also appreciably affect ET-1 activity. It is well known that EDRF suppresses ET-1 release [113] and endothelial damage itself is thought to be associated with increased release of ET-1 [6, 7, 114] . Moreover, ET receptor blockade restored EDRF function in a model of atherosclerosis, suggesting that ET-1 acts to inhibit EDRF in pathological states [51] . Such a link between changes in EDRF and endothelial function and the release and action of ET-1 might have a profound effect on ET-1 activity in diabetes (Fig. 4) . Accordingly, as diabetes progresses from diagnosis to end stage, changes in ET-1 release and action would vary in parallel with changes in EDRF and endothelial function. Indeed, we have shown that changes in plasma concentrations of ET-1 and vascular responses to ET-1 in STZ rats are duration-dependent and occur in parallel with changes in endothelial function [11] . Further studies are required to determine if this relation holds true in humans and if such changes are relevant to the pathophysiology of diabetic vascular complications.
Metabolic variables ± summary. It is clear that many of the well-known metabolic abnormalities encountered in diabetes contribute individually and synergistically to alterations in the release and action of ET-1. Further studies examining how ET blockers affect the sequelae of each of these abnormalities are required to determine the physiological relevance of these actions. Furthermore, examining how these factors interact in vivo and how current treatment options for the metabolic dysregulation of diabetes act to modulate ET-1 activity in diabetic humans assumes importance.
Conclusion
The diabetic state is associated with a multitude of metabolic abnormalities capable of directly and indirectly contributing to endothelial and VSM dysfunction and consequently affecting ET-1 release and action. The important role of ET-1 as a modulator of vascular tone and growth indicate that such changes might have important pathophysiological consequences in the development of diabetic vascular complications. To date, research has focused to a large extent on changes in vascular reactivity and circulating plasma concentrations of ET-1 in diabetes. Although easy to study, these variables give few clues as to its role in the disease. Antagonists of the ET system are rapidly progressing to the clinic for the treatment of cardiovascular conditions including congestive heart failure, cerebrovascular ischaemia and pulmonary hypertension. Groundbreaking recent studies in diabetic animal models indicate that blockers of the ET system might also beneficially affect and even reduce some of the complications of diabetes such as nephropathy and neuropathy. It is imperative that future studies be directed towards examining the effects of ET antagonists or ECE inhibitors or both on these and other complications in models of diabetes. Such studies will determine whether there is a definitive role for ET-1 in the pathogenesis of diabetic vascular disease. The effects of endothelin-1 and NG-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus. 
